SCHEMBL21403274

SCHEMBL21403274

COC(=O)c1c(Cl)cc(Cl)nc1NC=NO

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ TYK2 P29597 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ ABL1 P00519 1/20 0.31
▸ SRC P12931 1/20 0.31
▸ PLA2G2A P14555 1/20 0.31
▸ NQO2 P16083 3/20 0.31
▸ MRGPRX4 Q96LA9 1/20 0.30
▸ TSHR P16473 2/20 0.30
▸ HSD17B10 Q99714 2/20 0.30
▸ CA12 O43570 1/20 0.30
▸ CA1 P00915 1/20 0.30
▸ CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29886117 1.00 KDM4E (0.36) KDM4EL3MBTL1ALOX15ALDH1A1SMN1; SMN2
SCHEMBL21403273 1.00 KDM4E (0.36) KDM4EL3MBTL1ALOX15ALDH1A1SMN1; SMN2
SCHEMBL1710208 0.77 KDM4E (0.44) KDM4EL3MBTL1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL31682572 0.76 TUBB4A (0.44) KDM4EL3MBTL1ALOX15ALDH1A1SMN1; SMN2
SCHEMBL19958207 0.74 KDM4E (0.42) KDM4EL3MBTL1ALOX15ALDH1A1SMN1; SMN2
SCHEMBL19959594 0.74 KDM4E (0.42) KDM4EL3MBTL1ALOX15ALDH1A1SMN1; SMN2
SCHEMBL12380495 0.74 KDM4E (0.44) KDM4EL3MBTL1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL8521535 0.72 KDM4E (0.39) KDM4EL3MBTL1ALOX15ALDH1A1SMN1; SMN2
SCHEMBL17054798 0.72 KDM4E (0.40) KDM4EL3MBTL1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL24070302 0.71 KDM4E (0.42) KDM4EL3MBTL1ALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434238-B2 Method for producing triazolopyridine compound JAPAN TOBACCO INC. (JP) 2022-09-06 — — US disclosed
CN-110214139-B Process for producing triazolopyridine compound 日本烟草产业株式会社 2022-08-23 — — CN disclosed
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND SHIONOGI & CO., LTD. (JP) 2020-10-29 — — US disclosed
EP-3546459-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND Japan Tobacco, Inc. (JP) 2019-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND EPOR, PAH, THPO KDM4E 482/4885L3MBTL1 3230/4885ALOX15 2642/4885
US-11434238-B2 Method for producing triazolopyridine compound EPOR, PAH, THPO KDM4E 482/4885L3MBTL1 3230/4885ALOX15 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback